{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:44Z","timestamp":1788932384239,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,31]]},"DOI":"10.7759\/cureus.30919","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T17:30:44Z","timestamp":1667237444000},"source":"Crossref","is-referenced-by-count":9,"title":["The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?"],"prefix":"10.7759","author":[{"given":"Arafath","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehla","family":"Touheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzammil","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosab","family":"Hor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15070","article-title":"The efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: a systematic review and meta-analysis","volume":"13","author":"Tedesco S","year":"2021","unstructured":"Tedesco S, Gajaram G, Chida S, et al.. The efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: a systematic review and meta-analysis. Cureus. 2021, 13:e15070. 10.7759\/cureus.15070","journal-title":"Cureus"},{"key":"ref2","article-title":"MDMA to treat PTSD in adults","volume":"51","author":"Latimer D","year":"2021","unstructured":"Latimer D, Stocker MD, Sayers K, et al.. MDMA to treat PTSD in adults. Psychopharmacol Bull. 2021, 51:125-49.","journal-title":"Psychopharmacol Bull"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1612499","article-title":"Post-traumatic stress disorder","volume":"376","author":"Shalev A","year":"2017","unstructured":"Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017, 376:2459-69. 10.1056\/NEJMra1612499","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for the treatment of PTSD","volume":"23","author":"Krediet E","year":"2020","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020, 23:385-400. 10.1093\/ijnp\/pyaa018","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff CM","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, et al.. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020, 177:391-410. 10.1176\/appi.ajp.2019.19010035","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2035358","article-title":"Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine","volume":"31","author":"Averill LA","year":"2022","unstructured":"Averill LA, Abdallah CG. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs. 2022, 31:133-7. 10.1080\/13543784.2022.2035358","journal-title":"Expert Opin Investig Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120302","article-title":"Review of potential psychedelic treatments for PTSD","volume":"439","author":"Henner RL","year":"2022","unstructured":"Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022, 439:120302. 10.1016\/j.jns.2022.120302","journal-title":"J Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2050324518767442","article-title":"The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977-1985)","volume":"4","author":"Passie T","year":"2018","unstructured":"Passie T . The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977-1985). Drug Science. 2018, 4:1-19. 10.1177\/2050324518767442","journal-title":"Drug Science"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer MC","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011, 25:439-52. 10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230109","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants","volume":"12","author":"Sessa B","year":"2019","unstructured":"Sessa B, Sakal C, O'Brien S, Nutt D. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Rep. 2019, 12:e230109. 10.1136\/bcr-2019-230109","journal-title":"BMJ Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth AL","year":"2018","unstructured":"Danforth AL, Grob CS, Struble C, et al.. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology. 2018, 235:3137-48. 10.1007\/s00213-018-5010-9","journal-title":"Psychopharmacology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer MC","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, et al.. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019, 236:2735-45. 10.1007\/s00213-019-05249-5","journal-title":"Psychopharmacology (Berl)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek CM","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, et al.. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014, 9:1645-52. 10.1093\/scan\/nst161","journal-title":"Soc Cogn Affect Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114542454","article-title":"Differential effects of MDMA and methylphenidate on social cognition","volume":"28","author":"Schmid Y","year":"2014","unstructured":"Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol. 2014, 28:847-56. 10.1177\/0269881114542454","journal-title":"J Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171700263X","article-title":"Diminished medial prefrontal cortex activation during the recollection of stressful events is an acquired characteristic of PTSD","volume":"48","author":"Dahlgren MK","year":"2018","unstructured":"Dahlgren MK, Laifer LM, VanElzakker MB, et al.. Diminished medial prefrontal cortex activation during the recollection of stressful events is an acquired characteristic of PTSD. Psychol Med. 2018, 48:1128-38. 10.1017\/S003329171700263X","journal-title":"Psychol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso JC","year":"2008","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar MA, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008, 40:225-36. 10.1080\/02791072.2008.10400637","journal-title":"J Psychoactive Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study","volume":"27","author":"Mithoefer MC","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, et al.. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013, 27:28-39. 10.1177\/0269881112456611","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer MC","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, et al.. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018, 5:486-97. 10.1016\/S2215-0366(18)30135-4","journal-title":"Lancet Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia AA","year":"2019","unstructured":"Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019, 10:650. 10.3389\/fpsyt.2019.00650","journal-title":"Front Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2011.016","article-title":"The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine","volume":"392","author":"Steinkellner T","year":"2011","unstructured":"Steinkellner T, Freissmuth M, Sitte HH, Montgomery T. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem. 2011, 392:103-15. 10.1515\/BC.2011.016","journal-title":"Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects","volume":"45","author":"Holze F","year":"2020","unstructured":"Holze F, Vizeli P, M\u00fcller F, et al.. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020, 45:462-71. 10.1038\/s41386-019-0569-3","journal-title":"Neuropsychopharmacology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal DJ","year":"2018","unstructured":"Heal DJ, Gosden J, Smith SL. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology. 2018, 142:89-115. 10.1016\/j.neuropharm.2018.01.049","journal-title":"Neuropharmacology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00007","article-title":"The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports","volume":"12","author":"Sanz C","year":"2018","unstructured":"Sanz C, Zamberlan F, Erowid E, Erowid F, Tagliazucchi E. The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports. Front Neurosci. 2018, 12:7. 10.3389\/fnins.2018.00007","journal-title":"Front Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky EM","year":"2007","unstructured":"Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007, 39:13-9. 10.1080\/02791072.2007.10399860","journal-title":"J Psychoactive Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate CA Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, et al.. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006, 63:856-64. 10.1001\/archpsyc.63.8.856","journal-title":"Arch Gen Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond G","year":"2014","unstructured":"Fond G, Loundou A, Rabu C, et al.. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014, 231:3663-76. 10.1007\/s00213-014-3664-5","journal-title":"Psychopharmacology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson ST","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, et al.. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018, 175:150-8. 10.1176\/appi.ajp.2017.17040472","journal-title":"Am J Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough JW","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, et al.. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013, 170:1134-42. 10.1176\/appi.ajp.2013.13030392","journal-title":"Am J Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-017-0829-z","article-title":"Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic","volume":"19","author":"Krystal JH","year":"2017","unstructured":"Krystal JH, Abdallah CG, Averill LA, et al.. Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep. 2017, 19:74. 10.1007\/s11920-017-0829-z","journal-title":"Curr Psychiatry Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly C","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, et al.. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018, 23:3170-82. 10.1016\/j.celrep.2018.05.022","journal-title":"Cell Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder A","year":"2014","unstructured":"Feder A, Parides MK, Murrough JW, et al.. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014, 71:681-8. 10.1001\/jamapsychiatry.2014.62","journal-title":"JAMA Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott CS","year":"2018","unstructured":"Albott CS, Lim KO, Forbes MK, et al.. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry. 2018, 79:m11634. 10.4088\/JCP.17m11634","journal-title":"J Clin Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2018.03.006","article-title":"d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: a pilot study","volume":"1866","author":"Pradhan B","year":"2018","unstructured":"Pradhan B, Mitrev L, Moaddell R, Wainer IW. d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: a pilot study. Biochim Biophys Acta Proteins Proteom. 2018, 1866:831-9. 10.1016\/j.bbapap.2018.03.006","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot M","year":"2010","unstructured":"aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010, 67:139-45. 10.1016\/j.biopsych.2009.08.038","journal-title":"Biol Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2019.02.005","article-title":"Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder","volume":"29","author":"Aust S","year":"2019","unstructured":"Aust S, G\u00e4rtner M, Basso L, et al.. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur Neuropsychopharmacol. 2019, 29:529-38. 10.1016\/j.euroneuro.2019.02.005","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al.. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016, 30:1181-97. 10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson MW","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014, 28:983-92. 10.1177\/0269881114548296","journal-title":"J Psychopharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder","volume":"9","author":"Bogenschutz MP","year":"2018","unstructured":"Bogenschutz MP, Podrebarac SK, Duane JH, et al.. Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol. 2018, 9:100. 10.3389\/fphar.2018.00100","journal-title":"Front Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects","volume":"7","author":"Mueller F","year":"2017","unstructured":"Mueller F, Lenz C, Dolder PC, et al.. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017, 7:e1084. 10.1038\/tp.2017.54","journal-title":"Transl Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/da.20208","article-title":"Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings","volume":"24","author":"Francati V","year":"2007","unstructured":"Francati V, Vermetten E, Bremner JD. Functional neuroimaging studies in posttraumatic stress disorder: review of current methods and findings. Depress Anxiety. 2007, 24:202-18. 10.1002\/da.20208","journal-title":"Depress Anxiety"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx047","article-title":"Effect of psilocybin on empathy and moral decision-making","volume":"20","author":"Pokorny T","year":"2017","unstructured":"Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX. Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol. 2017, 20:747-57. 10.1093\/ijnp\/pyx047","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4026-7","article-title":"Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations","volume":"232","author":"Kometer M","year":"2015","unstructured":"Kometer M, Pokorny T, Seifritz E, Volleinweider FX. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology. 2015, 232:3663-76. 10.1007\/s00213-015-4026-7","journal-title":"Psychopharmacology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts R","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol. 2017, 57:520-64. 10.1177\/0022167817709585","journal-title":"J Humanist Psychol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman L","year":"2019","unstructured":"Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019, 33:1076-87. 10.1177\/0269881119855974","journal-title":"J Psychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson MW","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018, 142:143-66. 10.1016\/j.neuropharm.2018.05.012","journal-title":"Neuropharmacology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.162","article-title":"Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder","volume":"43","author":"Hill MN","year":"2018","unstructured":"Hill MN, Campolongo P, Yehuda R, Patel S. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018, 43:80-102. 10.1038\/npp.2017.162","journal-title":"Neuropsychopharmacology"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2020.22.3\/mcrocq","article-title":"History of cannabis and the endocannabinoid system","volume":"22","author":"Crocq MA","year":"2020","unstructured":"Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020, 22:223-8. 10.31887\/DCNS.2020.22.3\/mcrocq","journal-title":"Dialogues Clin Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1377","article-title":"Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence","volume":"4","author":"Passie T","year":"2012","unstructured":"Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012, 4:649-59. 10.1002\/dta.1377","journal-title":"Drug Test Anal"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l574","article-title":"WHO proposes rescheduling cannabis to allow medical applications","volume":"364","author":"Mayor S","year":"2019","unstructured":"Mayor S. WHO proposes rescheduling cannabis to allow medical applications. BMJ. 2019, 364:l574. 10.1136\/bmj.l574","journal-title":"BMJ"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32651-4","article-title":"A new ESI-LC\/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis","volume":"8","author":"Berman P","year":"2018","unstructured":"Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, Meiri D. A new ESI-LC\/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018, 8:14280. 10.1038\/s41598-018-32651-4","journal-title":"Sci Rep"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1141","article-title":"Medicinal use of cannabis based products and cannabinoids","volume":"365","author":"Freeman TP","year":"2019","unstructured":"Freeman TP, Hindocha C, Green SF, Bloomfield MA. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019, 365:l1141. 10.1136\/bmj.l1141","journal-title":"BMJ"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.03.017","article-title":"Cannabinoid interventions for PTSD: where to next?","volume":"93","author":"Ney LJ","year":"2019","unstructured":"Ney LJ, Matthews A, Bruno R, Felmingham KL. Cannabinoid interventions for PTSD: where to next?. Prog Neuropsychopharmacol Biol Psychiatry. 2019, 93:124-40. 10.1016\/j.pnpbp.2019.03.017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.166","article-title":"Neurobiological interactions between stress and the endocannabinoid system","volume":"41","author":"Morena M","year":"2016","unstructured":"Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016, 41:80-102. 10.1038\/npp.2015.166","journal-title":"Neuropsychopharmacology"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2013.09.009","article-title":"Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans","volume":"113","author":"Rabinak CA","year":"2014","unstructured":"Rabinak CA, Angstadt M, Lyons M, Mori S, Milad MR, Liberzon I, Phan KL. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem. 2014, 113:125-34. 10.1016\/j.nlm.2013.09.009","journal-title":"Neurobiol Learn Mem"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.07.024","article-title":"Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors","volume":"125","author":"Stern CA","year":"2017","unstructured":"Stern CA, da Silva TR, Raymundi AM, et al.. Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors. Neuropharmacology. 2017, 125:220-30. 10.1016\/j.neuropharm.2017.07.024","journal-title":"Neuropharmacology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.09.013","article-title":"Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity","volume":"69","author":"Norrholm SD","year":"2011","unstructured":"Norrholm SD, Jovanovic T, Olin IW, Sands LA, Karapanou I, Bradley B, Ressler KJ. Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry. 2011, 69:556-63. 10.1016\/j.biopsych.2010.09.013","journal-title":"Biol Psychiatry"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0212-3","article-title":"Preliminary, open-label, pilot study of add-on oral \u03949-tetrahydrocannabinol in chronic post-traumatic stress disorder","volume":"34","author":"Roitman P","year":"2014","unstructured":"Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral \u03949-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014, 34:587-91. 10.1007\/s40261-014-0212-3","journal-title":"Clin Drug Investig"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly R","year":"2015","unstructured":"Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015, 51:585-8. 10.1016\/j.psyneuen.2014.11.002","journal-title":"Psychoneuroendocrinology"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00071.x","article-title":"The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)","volume":"15","author":"Fraser GA","year":"2009","unstructured":"Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009, 15:84-8. 10.1111\/j.1755-5949.2008.00071.x","journal-title":"CNS Neurosci Ther"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000180","article-title":"Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation","volume":"34","author":"Cameron C","year":"2014","unstructured":"Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014, 34:559-64. 10.1097\/JCP.0000000000000180","journal-title":"J Clin Psychopharmacol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black N","year":"2019","unstructured":"Black N, Stockings E, Campbell G, et al.. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019, 6:995-1010. 10.1016\/S2215-0366(19)30401-8","journal-title":"Lancet Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"MacCallum CA","year":"2018","unstructured":"MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018, 49:12-9. 10.1016\/j.ejim.2018.01.004","journal-title":"Eur J Intern Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1407928","article-title":"Adverse health effects of marijuana use","volume":"371","author":"Wolff V","year":"2014","unstructured":"Wolff V, Rouyer O, Geny B. Adverse health effects of marijuana use. N Engl J Med. 2014, 371:878-9. 10.1056\/NEJMc1407928","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-019-1044-x","article-title":"Cannabis and psychosis: are we any closer to understanding the relationship?","volume":"21","author":"Hamilton I","year":"2019","unstructured":"Hamilton I, Monaghan M. Cannabis and psychosis: are we any closer to understanding the relationship?. Curr Psychiatry Rep. 2019, 21:48. 10.1007\/s11920-019-1044-x","journal-title":"Curr Psychiatry Rep"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15070907","article-title":"Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III","volume":"173","author":"Hasin DS","year":"2016","unstructured":"Hasin DS, Kerridge BT, Saha TD, et al.. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry. 2016, 173:588-99. 10.1176\/appi.ajp.2015.15070907","journal-title":"Am J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/120947-the-efficacy-of-psychedelic-assisted-therapy-in-managing-post-traumatic-stress-disorder-ptsd-a-new-frontier","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:50Z","timestamp":1707508070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/120947-the-efficacy-of-psychedelic-assisted-therapy-in-managing-post-traumatic-stress-disorder-ptsd-a-new-frontier"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":65,"URL":"https:\/\/doi.org\/10.7759\/cureus.30919","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}